Amberstone Biosciences is a biotechnology company developing tumor-activated immunotherapeutics. It utilizes the T-MATE technology to offer a solution that triggers immune responses in tumors while sparing healthy tissues. The company uses a discovery platform comprising microfluidics-based single-cell screening system, molecular evolution, combined annotation dependent depletion, AI, and machine learning.